
BioAegis Therapeutics develops biomarker treatments, restoring human protein levels to prevent inflammation.
BioAegis Therapeutics, founded with a mission to combat inflammatory diseases, focuses on developing biomarker-directed treatments that restore depleted levels of plasma gelsolin, a natural human protein. This protein plays a crucial role in preventing the spread of inflammation, potentially averting multiple organ dysfunction syndrome. The company targets the healthcare industry, aiming to provide innovative solutions for conditions related to inflammation and infection.
Notable achievements include securing a $20 million BARDA DRIVe contract in October 2023 to advance treatments for Acute Respiratory Distress Syndrome (ARDS). BioAegis Therapeutics has made significant strides in clinical stages, leveraging its unique approach to harness innate immunity. The company's impactful work in restoring human protein levels has positioned it as a promising player in the field of inflammatory disease therapeutics.

Elgia Therapeutics

ProThera Biologics

Aibios
aibios.com

Therini Bio
therinibio.com

Spyre Therapeutics
aeglea.com

Quench Bio

HI-Bio
hibio.com

NeurAegis
neuraegis.com

Bond Biosciences
bond.bio

Aegle Therapeutics
GEn1E Lifesciences
gen1e.com

Biomarck Pharmaceuticals

Equillium
equilliumbio.com

Biotheryx
biotheryx.com

Palisade Bio
palisadebio.com
Companies similar to BioAegis Therapeutics include Elgia Therapeutics, ProThera Biologics, Aibios and Therini Bio.
BioAegis Therapeutics was founded in 2011.
BioAegis Therapeutics' headquarters is located in North Brunswick, NJ, US.
BioAegis Therapeutics' most recent funding round was for $22M (USD) in March 2022.
As of Mar 22, 2022, BioAegis Therapeutics has raised a total of $42.3M (USD).
BioAegis Therapeutics has 13 employees as of Feb 5, 2024.